Incorporated in 1993, Syngene is an integrated research, development, and manufacturing organization specializing in both small and large molecules. Our capabilities cater to a broad range of sectors, including global pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals.
We offer specialist stand-alone activities and longer-term programs that accelerate the progress of a molecule from discovery to market. Our extensive experience and expertise have made us a trusted partner to global multinationals, small and mediumsized enterprises, non-profit institutions, academic entities, and government organizations.
We recognize our corporate responsibilities and strive to deliver sustainable benefits to society while fulfilling the expectations of clients and regulatory authorities. Our commitment to high environmental, social, and governance (ESG) performance is integral to our business strategy. We focus on minimizing our environmental footprint, enhancing employee safety and well‑being and positively impacting the communities where we operate.
Syngene is listed on the Indian stock exchanges.
Our workforce, comprising over 8,146 employees and workers (as of March 31, 2024), including more than 5,656 scientists, forms the backbone of our operations. Our team also includes specialists and professionals across various functions who ensure smooth project delivery. We emphasize scientific integrity, compliance, and high performance, aligning our workforce with our core values and objectives.
Syngene is headquartered in Bangalore, India, where our main campus serves as the central hub for our research, development and manufacturing operations. We also operate three satellite campuses in Bangalore, which houses essential functions including Human Resources, Legal, and Finance, as well as our Clinical Development facility. To further support our expanding research operations, we have established an additional campus in Hyderabad. Our facility in Mangalore is dedicated to the commercial-scale production of active pharmaceutical ingredients (APIs). Globally, our outreach is extended through Syngene USA Inc., which supports our clients in the United States, and through our commercial teams based locally in the United Kingdom and Europe.
Our Discovery Services division is responsible for conducting early-stage research, from identifying biological targets relevant to diseases in patient populations to delivering drug candidates for further development. Our capabilities encompass chemistry, biology, safety assessment, and computational and data sciences. We cater to traditional small molecule therapeutics, biologics, and specialty modalities such as peptides, oligonucleotides, antibodydrug conjugates, and targeted degradation/stabilization. Syngene SynVent™, a part of our Discovery Services, is our platform for integrated drug discovery that offers clients complete project delivery capabilities, utilizing our differentiated technologies and scientific expertise.
The Dedicated R&D Center division provides a turnkey solution for clients seeking to establish and operate a dedicated research center on a large scale without the need for long-term capital investments. This service enables seamless integration into the client’s internal research network while maintaining the flexibility to scale operations up or down as needed. Each R&D Center is staffed by a dedicated, multi-disciplinary team of scientists and support personnel. Currently, this division serves three major clients: Amgen, Baxter, and Bristol Myers Squibb.
Focusing on small molecules, our Development Services division takes drug candidates and provides a comprehensive range of services from pre-clinical to clinical trials. This includes the development of drug substances and drug products, alongside associated services to demonstrate the safety, tolerability, and efficacy of drugs. Our development capabilities extend to advancing highly potent active pharmaceutical ingredients and oligonucleotides for both therapeutic and diagnostic applications, scaling from laboratory to manufacturing levels. Our expertise also encompasses working with performance chemicals and specialty materials, utilizing synthetic organic chemistry and polymer chemistry. We integrate analytical services throughout the development process, including method development, validation, transfer, and reference standard qualification.
The Manufacturing Services division provides commercial-scale manufacturing of both small and large molecules. Our small molecule production is carried out at our US FDA-compliant API manufacturing campus in Mangalore. For large molecules, development and manufacturing services are provided from our biologics facility in Bangalore, approved by the US and European regulatory authorities. We have also recently acquired a multi-modal biologics manufacturing facility, which is expected to become operational in 2024 following facility upgrades and re-validation.
